Atoderm AD Intensive Baume

IMMEDIATE BENEFITS:

1) SOOTHES IMMEDIATLY ITCHING OF PATIENTS WITH ATOPIC DERMATITIS: 

> From 1 second for 100% (1A);

> -55% itching after 1min (p<0.001 versus t0) (1B);

> -82% itching after 1 hour (p<0.001 versus t0) (1B);

2) PROTECTS FROM TRIGGERING FACTORS FROM THE VERY 1ST USE:

> Shield effects againt the following triggering factors: -92% cat allergen (2), -85% peanut allergen (2), -81% mold allergen (2), -71% dust mite allergen (2), -80% pollution particles (3), -58% skin adherence (4) and -99.9% proliferation as a biofilm of S. aureus (5).

LASTING BENEFITS:

1) SOOTHES ITCHING SENSATIONS LASTINGLY:

> 8X less urge to scratch after 1 month (p<0.001 versus D0) (6)

> 6 months without flare-ups for 88% of atopic patients (7A), and with 100% of atopic patients with reduction of flares number compared to the previous 6-month period.

2) PROTECTS LASTINGLY FROM TRIGGERING FACTORS PENETRATION IN SKIN:

> Relauches biological synthesis of key elements in epidermis : +180% loricrin  (8), +22% filaggrin (8), +51% long-chain ceramides (9), +250% claudin-1  (10);

> Rebuilds skin barrier: -29% TEWL after 8 days (11);

3) IMPROVE QUALITY OF LIFE OF CHILDREN WITH LIGHT TO MODERATE AD, STATISTICALLY BETTER THAN NEUTRAL CREAM:

> Atopic eczema-prone skin has 3X less impact on social activities and daily life (7B), with -50% CDLQI after 4 months (p<0.001 versus D0, p<0.01 versus neutral cream) (7).

> Sleep recovers quality: -92% insomnia after 6 months (p<0.001 versus D0, p<0.01 versus neutral cream) (7C)

> Skin regains comfort and a healthy appearance: -79% patches extend (SCORAD-A) (7C), -84% xerosis (7C), -76% erythema (7C) after 6 months (p<0.001 versus D0, p<0.001 versus neutral cream).

FAVORS COMPLIANCE:

> The cosmetic properties of the product promote/encourage the compliance to use it every day (for 96%) (1C);

> The product’s effectiveness promotes/encourages the compliance to use it every day (for 93%) (1C);

TOLERANCE:

Very good skin tolerance on body and face from birth, even in association of topical corticosteroids (7,11)

The product doesn't make the skin sting just after application (for 96%) (1C).

Soothes itching instantly :  From 1 second (1); 8x less scratch urge (5)

Prevents flare-ups over time : 6 months without flare-ups (for 88% of subjects) (7A)

Reduces pruritus durably : 7x less pruritus after 6 months (7C)

Efficacy tested on atopic patients versus neutral cream (7,11).

Cavallo A, Camera E, Bottillo G, Maiellaro M, Truglio M, Marini F, Chavagnac-Bonneville M, Fauger A, Perrier E, Pigliacelli F, Picardo M, Cristaudo A, Mariano M. Biosignatures of defective sebaceous gland activity in sebum-rich and sebum-poor skin areas in adult atopic dermatitis. Exp Dermatol. 2024 Mar;33(3):e15066.

1.Clinical study under dermatological control, on 30 adult subjects with chronic atopic dermatitis and significant pruritus using Atoderm AD Intensive baume for 7 days. A/ Self-assessment of the soothing efficacy under medical control after the first application. B/ Self-grading under medical control after the first application, Wilcoxon signed-rank tests. C/ Self-assessment after 7 days of use (Argentina, 2025).2.Ex vivo study of physical protection against allergens penetration by Atoderm AD Intensive baume on skin biopsies, versus untreated condition. Allergens tested:  Der p1 for dust mite (p<0.001), Fel d1 for cat (p<0.001), Ara h2 for peanut (p<0.001), Alt a1 for Mold (p<0.01). Quantification by immunostaining and image analysis. Unpaired t-test versus allergen alone condition (France, 2025).3.Clinical study on 10 subjects, evaluation of physical protection of Atoderm AD Intensive baume against pollution particles deposition on skin. Instrumental measure by colorimetry. Student t-test, p<0.001 versus control area (France, 2024)4.Ex vivo study of adhesion of Staphylococcus aureus to human corneocytes, with SKIN BARRIER THERAPY technology versus control condition. Counting of bacteria after 1h-incubation (France, 2013)5.In vitro study of protection efficacy of Atoderm AD Intensive baume against proliferation of Staphylococcus aureus under biofilm form, versus control condition. Counting of bacteria after 4h-incubation (France, 2024)6.Clinical study under dermatological control, on 32 adult subjects with irritant or allergic contact dermatitis, using Atoderm AD Intensive baume for 28 days. Self-grading. Student or Friedmann or Wilcoxon test (Mauritius, 2025).7.Clinical study under dermatological and pediatric control, on 88 children with light to moderate atopic dermatitis, using either Atoderm AD Intensive baume or a neutral cream, for 6 months. A/ Self-reporting: 88% of subjects without any reported flare-ups for 6 months with Atoderm AD Intensive baume. B/ Self-grading of CDLQI, question n°3 “Over the last week, how much has your skin affected your friendship?” (-70% versus neutral cream at 6 months, p<0.01 Mann-Whitney), and question n°5 after 4 months “Over the last week, how much has your skin trouble affected going out, playing or doing hobbies?” (-67% versus neutral cream at 4 months, p<0.01 Mann-Whitney). C/ Clinical grading, sub-score of SCORAD, paired t-test or Wilcoxon signed-rank test versus D0, Mann-Whitney versus neutral cream group (Poland, 2024-2025).8.Ex vivo study of loricrin and filaggrin synthesis by cytokines-stressed skin biopsies, after LIPIDACTIVE technology topical application versus stressed untreated condition. Quantification by immunostaining of proteins and image analysis (France, 2024).9.Ex vivo study of ceramides synthesis by stripped skin biopsies, after LIPIDACTIVE technology topical application versus stripped untreated condition. Quantification by liquid chromatography and mass spectrometry. +51% NP long-chain ceramides (France, 2025).10.In vitro study of claudin-1 (tight junctions) synthesis by stressed human primary keratinocytes, with SKIN BARRIER SEALER technology versus stressed control condition. Quantification by immunostaining of proteins and image analysis (France, 2020)11.Clinical study under dermatological control, on 43 adult subjects with moderate atopic dermatitis using either Atoderm AD Intensive baume or a neutral cream, in routine with Atoderm Huile de douche, for 37 days. Subjects also used topical corticosteroid on lesional areas for the first 8 days. Instrumental measure on non-lesional area. p<0.001 versus D0, p<0.05 versus neutral cream group (Georgia, winter 2025).